Deciphera Pharmaceuticals, Inc. to Present at the UBS Global Healthcare Conference
May 14 2019 - 4:05PM
Business Wire
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage
biopharmaceutical company focused on addressing key mechanisms of
tumor drug resistance, today announced that Steve Hoerter,
President and Chief Executive Officer, will present at the UBS
Global Healthcare Conference on Monday, May 20 at 9:00 AM ET at the
Grand Hyatt New York.
A live webcast of the event will be available on the “Events and
Presentations” page in the “Investors” section of the Company’s
website at
https://investors.deciphera.com/news-events/events-presentations. A
replay of the webcast will be archived on the Company’s website for
90 days following the presentation.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage
biopharmaceutical company focused on improving the lives of cancer
patients by tackling key mechanisms of drug resistance that limit
the rate and/or durability of response to existing cancer
therapies. Our small molecule drug candidates are directed against
an important family of enzymes called kinases, known to be directly
involved in the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary
chemistry library to purposefully design compounds that maintain
kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed
to address therapeutic resistance causing mutations and
immuno-targeted agents designed to control the activation of
immunokinases that suppress critical immune system regulators, such
as macrophages. We have used our platform to develop a diverse
pipeline of tumor-targeted and immuno-targeted drug candidates
designed to improve outcomes for patients with cancer by improving
the quality, rate and/or durability of their responses to
treatment.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190514005947/en/
Investor Relations:Jen RobinsonDeciphera Pharmaceuticals,
Inc.jrobinson@deciphera.com781-906-1112
Media:Gina Nugent, The Yates
Networkgina@theyatesnetwork.com617-460-3579
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Apr 2023 to Apr 2024